Pfizer Inc. (PFE) expects to pay at least $772 million to resolve all of the product-liability litigation surrounding its hormone-replacement therapy drugs, but the ultimate tally could be higher. Pfizer inherited much of the litigation through its 2009 purchase of Wyeth, maker of hormone-therapy drugs including PremPro, which treat conditions associated with menopause such as hot flashes. Nearly a decade ago, government-sponsored studies began showing the drugs were associated with increased risk of breast cancer and other adverse events, which spurred thousands of lawsuits by women or their families claiming the drugs caused injuries.
